Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | CCR9 | P51686 | 3/20 | 0.34 |
| ▸ | MC4R | P32245 | 3/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038223 | 0.85 | VNN1 (0.39) | PANK3CDK4HSD11B1SCN9AMC4R | |
| SCHEMBL20249273 | 0.83 | PANK3 (0.45) | PANK3CDK4CCR9KDM4ESMN1; SMN2 | |
| SCHEMBL20038221 | 0.83 | HSD11B1 (0.37) | PANK3CDK4HSD11B1SCN9AMC4R | |
| SCHEMBL18291376 | 0.83 | GABRP (0.46) | CDK4HSD11B1SCN9AMC4RGHSR | |
| SCHEMBL18291302 | 0.82 | PANK3 (0.51) | PANK3CDK4HSD11B1SCN9AMC4R | |
| SCHEMBL20249140 | 0.78 | IDH1 (0.38) | CCR9 | |
| SCHEMBL20249329 | 0.75 | HRH3 (0.46) | PANK3KDM4ESMN1; SMN2 | |
| SCHEMBL20249321 | 0.72 | KCNJ1 (0.44) | PANK3HSD11B1KDM4ESMN1; SMN2 | |
| SCHEMBL13768896 | 0.71 | CDK4 (0.47) | PANK3CDK4HSD11B1SMN1; SMN2 | |
| SCHEMBL12040428 | 0.68 | CA2 (0.46) | CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PANK3 492/4885CDK4 1/4885HSD11B1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.